Top Companies in CAR T-cell Therapy (2024)
At first, the trend was subtle. But, the tide has swelled and created a craze for promising CAR-T product candidates. Driven by approvals of the CAR-T products Kymriah and Yescarta, there has been a rush to chase the next CAR-T success. CAR T-cell therapy (Chimeric Antigen Receptor T-Cell) is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” The global CAR T-cell therapy market size was valued at USD 2.75 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 23.32% from 2023 to 2030. Remarkable success in treating blood cancers, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) has increased the adoption of CAR T-cell therapy and is anticipated to boost the industry's growth ( Grand View Research ). This article p...